At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 168 enrolled
Drug / intervention
Certolizumab pegoldrug
Likely dose
Certolizumab pegol 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIIb, Multi-center Open-label, Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With Methotrexate in Patients With Active Rheumatoid Arthritis Who Participated in C87077.
In Brief
A Phase 3 clinical trial evaluating Certolizumab pegol for Rheumatoid Arthritis. Completed, enrolled 168 participants across 40 sites in 2 countries.
Detailed Summary
The purpose of this study is to continue to assess the safety of certolizumab pegol in combination with methotrexate (MTX).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedSep 2008
Primary CompletionMay 2011
TodayJul 2026
First PostedSep 16, 2008
Enrollment StartSep 1, 2008
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 17.8 years ago
Interventions
Certolizumab pegoldrug
Liquid certolizumab pegol administered every two weeks as a single injection (400 mg at Entry, Week 2 \& Week 4, followed by 200 mg every 2 weeks).